AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26872253 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 28
Study 26872253 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28
Study 26872253 — intervention group
Group type: COMPARATOR
Intervention: Physical training (both types)
Number of subjects: 28
Study 24326421 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 125 mg/wk) + Finasteride (5 mg/day)
Number of subjects: 60
Study 24326421 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE; 125 mg/wk)
Number of subjects: 60
Study 22309826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI training
Number of subjects: 63
Study 22309826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock training
Number of subjects: 63
Study 22309826 — intervention group
Group type: COMPARATOR
Intervention: Lab training
Number of subjects: 63
Study 22309826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and mock training
Number of subjects: 63
Study 22309826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock and MRI groups
Number of subjects: 63
Study 22309826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both days
Number of subjects: 63
Study 21166272 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-first group (n = 8)
Number of subjects: 17
Study 21166272 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-later group (n = 9)
Number of subjects: 17
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized therapeutic trials
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Levels of Evidence
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Coleman Methodology Score
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT score
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment descriptions
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-level calculations
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant flow
Number of subjects: 54
Study 17671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up, sample size, and blinding
Number of subjects: 54
Study 15763716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) intervention
Number of subjects: 56
Study 15763716 — intervention group
Group type: COMPARATOR
Intervention: Low intensity comparison condition
Number of subjects: 56
Study 11943947 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 16
Study 11943947 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 16
Study 9463749 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of urinary retinol-binding protein (RBP)
Number of subjects: 150
Study 9463749 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of beta-2-glycoprotein-1 (beta 2G1)
Number of subjects: 150
Study 7623462 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol (mean blood alcohol concentration 0.043%)
Number of subjects: 8
Study 7623462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol (mean blood alcohol concentration 0.011%)
Number of subjects: 8
Study 7623462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7623462 — intervention group
Group type: COMPARATOR
Intervention: No beverage (control session)
Number of subjects: 8
Study 2201266 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant treatment
Number of subjects: 231
Study 2201266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 231
Study 2201266 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 231
Study 195208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (vidarabine)
Number of subjects: 28
Study 195208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30921977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve block
Number of subjects: 80
Study 30921977 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided genicular nerve block
Number of subjects: 80
Study 28124224 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 156
Study 28124224 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 156
Study 25627076 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 40
Study 25627076 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 40
Study 23598724 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylene exposure
Number of subjects: 30
Study 23598724 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed participants)
Number of subjects: 30
Study 22151512 — intervention group
Group type: EXPERIMENTAL
Intervention: Making a Difference! (MAD)
Number of subjects: 2016
Study 22151512 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Number of subjects: 2016
Study 22151512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FTT+MAD intervention
Number of subjects: 2016
Study 19152520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 5-aminolevulinic acid (ALA)
Number of subjects: 0
Study 19152520 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (PDT)
Number of subjects: 0
Study 17411413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based syringe exchange program (SEP)
Number of subjects: 166
Study 17411413 — intervention group
Group type: COMPARATOR
Intervention: Community-based syringe exchange program (SEP)
Number of subjects: 166
Study 16201049 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic fixed-dose combinations (rifampicin 120 mg, isoniazid 80 mg, pyrazinamide 250 mg for 2 months; rifampicin 300 mg, isoniazid 150 mg for 4 months)
Number of subjects: 422
Study 16201049 — intervention group
Group type: COMPARATOR
Intervention: Full 6-month standard regimens (2HRZE/4H3R3)
Number of subjects: 422
Study 16201049 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic fixed-dose combinations
Number of subjects: 422
Study 16201049 — intervention group
Group type: COMPARATOR
Intervention: Full 6-month standard regimens
Number of subjects: 422
Study 11098962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1-0.35 mg/kg/hr)
Number of subjects: 63
Study 11098962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Propofol (1.5-6 mg/kg/hr)
Number of subjects: 63
Study 11098962 — intervention group
Group type: COMPARATOR
Intervention: 1% Propofol (retrospective comparison)
Number of subjects: 63
Study 11098962 — intervention group
Group type: COMPARATOR
Intervention: 2% Propofol
Number of subjects: 63
Study 9031577 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration during a 4-week double-blind and placebo-controlled study with a 2-week single-blind placebo lead-in period.
Number of subjects: 44
Study 9031577 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient milieu/structure (non-pharmacological intervention)
Number of subjects: 44
Study 9031577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8341050 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually focused cognitive behavioral (CB) treatment
Number of subjects: 0
Study 8341050 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship enhancement (RE) of brief cognitive behavioral treatments
Number of subjects: 0
Study 8341050 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing alcohol-specific support
Number of subjects: 0
Study 3330184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11
Study 3330184 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 11
Study 3330184 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg chlorpromazine
Number of subjects: 11
Study 3330184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29306817 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic brief intervention (assessment of drinking and personalized feedback) and referral
Number of subjects: 123
Study 29306817 — intervention group
Group type: COMPARATOR
Intervention: Referral alone (control)
Number of subjects: 123
Study 28923720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa Damascena oil (RDO)
Number of subjects: 50
Study 28923720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26038078 — intervention group
Group type: EXPERIMENTAL
Intervention: Light buccopalatal jiggling forces (25 g)
Number of subjects: 30
Study 26038078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy buccopalatal jiggling forces (225 g)
Number of subjects: 30
Study 26038078 — intervention group
Group type: COMPARATOR
Intervention: Continuous buccal forces (positive control)
Number of subjects: 30
Study 23672772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct extended-release quetiapine fumarate (quetiapine XR) 150 mg/d
Number of subjects: 919
Study 23672772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct extended-release quetiapine fumarate (quetiapine XR) 300 mg/d
Number of subjects: 919
Study 23672772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study 21248600 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Education Progress-Testing (SEPT)
Number of subjects: 2648
Study 21248600 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal Progress-Testing Alone (LPTA)
Number of subjects: 2648
Study 18288327 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 267
Study 18288327 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior occlusal surface‐years
Number of subjects: 267
Study 17675895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular case management program (6 months)
Number of subjects: 450
Study 17675895 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study 12873621 — intervention group
Group type: EXPERIMENTAL
Intervention: THC infusion and marijuana smoking
Number of subjects: 29
Study 12873621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study 10416877 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestational drugs
Number of subjects: 8
Study 10416877 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 8
Study 9005424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosigmoidoscopy
Number of subjects: 2405
Study 1919882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing diet (Suc-Con, 10% total calories from sucrose)
Number of subjects: 10
Study 1919882 — intervention group
Group type: COMPARATOR
Intervention: Traditional sucrose-free diet (Suc-Free, 2% total calories from sucrose)
Number of subjects: 10
Study 1919882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing diet (Suc-Con)
Number of subjects: 10
Study 1919882 — intervention group
Group type: COMPARATOR
Intervention: Traditional sucrose-free diet (Suc-Free)
Number of subjects: 10
Study 1919882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 10
Study 6962421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus B.C.G.
Number of subjects: 64
Study 6962421 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 64
Study 31149869 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week workplace cycling intervention (n = 12)
Number of subjects: 21
Study 27741414 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozone therapy
Number of subjects: 33
Study 27741414 — intervention group
Group type: COMPARATOR
Intervention: Control group (systemic antibiotics only)
Number of subjects: 33
Study 26485385 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of lidocaine with 1 mg of morphine (MLA group)
Number of subjects: 48
Study 26485385 — intervention group
Group type: COMPARATOR
Intervention: Local injection of lidocaine alone (LA group)
Number of subjects: 48
Study 26485385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MLA and LA)
Number of subjects: 48
Study 23569029 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg Uceris®
Number of subjects: 12
Study 23569029 — intervention group
Group type: COMPARATOR
Intervention: 9 mg Entocort® EC
Number of subjects: 12
Study 22156352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate 30 g/day for fifteen days
Number of subjects: 32
Study 22156352 — intervention group
Group type: COMPARATOR
Intervention: White chocolate 25 g/day for fifteen days (Control)
Number of subjects: 32
Study 19827910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone/metformin fixed-dose combination (FDC) therapy
Number of subjects: 0
Study 19827910 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 0
Study 19827910 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0
Study 19827910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone/metformin FDC therapy
Number of subjects: 0
Study 16913318 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG)
Number of subjects: 0
Study 16913318 — intervention group
Group type: COMPARATOR
Intervention: Control group (thermodilution via pulmonary artery catheter)
Number of subjects: 0
Study 14742288 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cellular telephones for 10 years or more
Number of subjects: 318
Study 14742288 — intervention group
Group type: COMPARATOR
Intervention: Short-term cellular telephone users
Number of subjects: 318
Study 14742288 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical side of head used for cell phone
Number of subjects: 318
Study 14742288 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of tumor
Number of subjects: 318
Study 12076550 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual outreach
Number of subjects: 2094
Study 12076550 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 2094
Study 9861140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 27
Study 9861140 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 27
Study 9861140 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 27
Study 7495240 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 30
Study 7495240 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied beta‐trans retinoic acid
Number of subjects: 30
Study 7495240 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 30
Study 2253571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprivan
Number of subjects: 40
Study 2253571 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 40
Study 388395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 30
Study 388395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 30
Study 388395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 388395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (24 months)
Number of subjects: 30
Study 6313376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg daily for 4 weeks
Number of subjects: 50
Study 6313376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6313376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg daily
Number of subjects: 50
Study 29352654 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 11
Study 29352654 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment Control (CON)
Number of subjects: 11
Study 29628560 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 120
Study 29628560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 120
Study 29628560 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 120
Study 27955689 — intervention group
Group type: EXPERIMENTAL
Intervention: MAT + A-CHESS
Number of subjects: 440
Study 27955689 — intervention group
Group type: COMPARATOR
Intervention: MAT
Number of subjects: 440
Study 25385729 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 379
Study 25385729 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 379
Study 22577905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in obese group (BMI ≥ 27.5 kg/m(2))
Number of subjects: 108
Study 22577905 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in non-obese group (BMI <27.5 kg/m(2))
Number of subjects: 108
Study 20795382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubo-M vaccine
Number of subjects: 63
Study 20795382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 63
Study 20795382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubo-M vaccine and hepatitis B vaccine
Number of subjects: 63
Study 17510847 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety kit plus home visit
Number of subjects: 0
Study 17510847 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety kit only
Number of subjects: 0
Study 17510847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 16238909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 290
Study 16238909 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir 400 mg boosted with ritonavir 100 mg twice daily
Number of subjects: 290
Study 12056230 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10072409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retreatment
Number of subjects: 100
Study 10072409 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 8771126 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Laserdish lead (Group A)
Number of subjects: 30
Study 8771126 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-iridium coated modified Laserdish electrode (Group B)
Number of subjects: 30
Study 8771126 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-iridium coated dish electrode without laser pores (Group C)
Number of subjects: 30
Study 8771126 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode with pores and platinum-iridium coating (Group B)
Number of subjects: 30
Study 8771126 — intervention group
Group type: COMPARATOR
Intervention: Electrode with pores (Group A)
Number of subjects: 30
Study 8771126 — intervention group
Group type: COMPARATOR
Intervention: Platinum-iridium alone (Group C)
Number of subjects: 30
Study 2205598 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 2205598 — intervention group
Group type: COMPARATOR
Intervention: Lithium Carbonate
Number of subjects: 0
Study 7017103 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 17
Study 7017103 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by periodontal surgery (modified Widman flap)
Number of subjects: 17
Study 31556454 — intervention group
Group type: EXPERIMENTAL
Intervention: iNIBP™
Number of subjects: 66
Study 31556454 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-invasive blood pressure monitor
Number of subjects: 66
Study 29792081 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-developed treatment (small-group tutoring for 30 to 45 minutes for an average of 68 lessons, mean hours of instruction = 44.4, SD = 11.2)
Number of subjects: 280
Study 29792081 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (BAU) comparison condition
Number of subjects: 280
Study 28838679 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial saliva (AS) with xylitol, sorbitol, maltitol, mannitol
Number of subjects: 0
Study 28838679 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial saliva (AS) with CPP-ACP
Number of subjects: 0
Study 28838679 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (AS) without polyols
Number of subjects: 0
Study 25983187 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachable moment brief intervention plus usual care
Number of subjects: 50
Study 25983187 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 50
Study 25746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of randomization
Number of subjects: 203
Study 25746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of placebo use
Number of subjects: 203
Study 25746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of double-blinding
Number of subjects: 203
Study 25746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of personal implications of study procedures
Number of subjects: 203
Study 25746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined understanding of randomization, double-blinding, and placebo use
Number of subjects: 203
Study 22878802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents
Number of subjects: 171
Study 19506270 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal multimicronutrient supplementation
Number of subjects: 0
Study 19506270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19506270 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid supplementation
Number of subjects: 0